RESEARCH ARTICLE

Association of Hyperuricemia and Urinary Albumin Excretion with Glycosylated Hemoglobin in Patients with Type II Diabetes Mellitus

[1]Bushra Fiza, [2]Jai P Yogi, [3]Jaishree Choudhary, [4]Anita Semar, [5]Maheep Sinha

ABSTRACT

Type II diabetes mellitus (DM) is the most common endocrine disorder and a leading cause of morbidity and mortality across the world. Long-standing diabetes and a poor glycemic control are the major factors which contribute to the development of various microvascular complications of diabetes. Microvascular changes in kidneys lead to microalbuminuria, which may further lead to end-stage renal disease (ESRD) if left untreated. Elevated serum uric acid level has been recognized as a marker of endothelial dysfunction which contributes to the development of microvascular changes in various organs. The main objective of the present study was to assess the association of serum uric acid and urine microalbumin levels with glycosylated hemoglobin (HbA1c) in type II DM patients. One hundred diagnosed cases of type II DM were enrolled for the study. Blood samples were collected and estimated for fasting blood sugar, serum uric acid, and HbA1c. Also, 24-hour urine samples were collected and analyzed for microalbumin. A positive association (r = 0.203) was observed between HbA1c and serum uric acid. The study also suggested a positive association between glycemic control and microalbuminuria (r = 0.237) in diabetic patients. A strong positive association was also observed between uric acid and urine microalbumin levels (r = 0.338). Findings of the study, therefore, recommend that development of microvascular complications in type II DM patients can be averted by adopting dietary control and healthy lifestyle changes. Strict glycemic control and lowering of serum uric acid levels can be helpful in minimizing the risk of developing nephropathy and its progression toward ESRD.

Keywords: Diabetes mellitus, Glycemic control, Glycosylated hemoglobin, Microalbuminuria, Nephropathy, Uric acid.

How to cite this article: Fiza B, Yogi JP, Choudhary J, Semar A, Sinha M. Association of Hyperuricemia and Urinary Albumin Excretion with Glycosylated Hemoglobin in Patients with Type II Diabetes Mellitus. J Mahatma Gandhi Univ Med Sci Tech 2017;2(1):1-6.

[1]Associate Professor, [2]Demonstrator, [3]PhD Student, [4]Senior Technical Assistant, [5]Professor and Head

[1-5]Department of Biochemistry, Mahatma Gandhi Medical College & Hospital, Jaipur, Rajasthan, India

Corresponding Author: Bushra Fiza, Type I/202, Staff Quarters Mahatma Gandhi Medical College & Hospital, Jaipur-302022 Rajasthan, India, Phone: +919828051780, e-mail: bushrafiza786 @gmail.com

INTRODUCTION

Type II diabetes mellitus (DM) is a nonautoimmune, complex, heterogeneous, and polygenic metabolic disease condition in which the body fails to produce enough insulin and hence characterized by abnormal glucose homeostasis.[1] Metabolic derangement syndrome is one of the causes of DM, and it is frequently associated with permanent and irreversible functional and structural changes in the cells of the body, particularly vascular system changes which lead in turn to the development of well-defined clinical entities, which are called the complications of DM that affect the eye, kidney, and the microvascular and nervous systems.

Diabetes mellitus has become a major health problem in India. It has been estimated that by the year 2030, 87 million of the Indian population would be suffering from this disease. Long-standing type II DM has considerable impact on various organs of the body. It increases morbidity and mortality by decreasing the quality of life.[2,3] Currently, India leads the world with the largest number of diabetic subjects and this is expected to further rise in the coming years.[4] Studies on diabetes-related complications are, therefore, vital to assess the burden of diabetes.

Diabetic nephropathy is one of the most common causes for end-stage renal disease (ESRD).[5-7] The early nephropathy stage when urinary albumin excretion is 30 to 300 mg/24 hours or 20 to 200 μg/minute is known as microalbuminuria, and patients with microalbuminuria are referred to as having initial nephropathy.[8] Intervention at this stage can retard or reverse the progression of nephropathy. Diabetic nephropathy in patients with type II diabetes has a growing prevalence of 35 to 40% and is presently the leading cause of ESRD.[9]

Epidemiological statistics exhibit that microalbuminuria amplifies the risk development of cardiovascular and cardiac abnormalities as well as cerebrovascular disease.[10] Recent findings suggest that uric acid is an inflammatory factor and may have a role in endothelial dysfunction and act as a mediator of diabetic nephropathy.[11-13]

Glycosylated hemoglobin (HbA1c) reflects an average blood glucose level over the past 3 months and has been recommended by the American Diabetes Association for evaluating the glycemic control of diabetic patients.[14] Few studies have suggested a positive correlation between microalbuminuria and HbA1c.[15-17] However, this association has not been established yet.

The present study was planned to assess the association of HbA1c (a marker of glycemic control) with serum uric acid and microalbuminuria in type II DM.

MATERIALS AND METHODS

The study was a single-center observational study conducted on type II diabetic patients visiting the Medicine Outpatient Department of Mahatma Gandhi Medical College & Hospital, Jaipur, India. The study was conducted after seeking approval from the Institutional Ethics Committee. One hundred clinically diagnosed type II DM patients were enrolled for the study. The criteria for inclusion were diagnosed cases of type II DM, age between 40 and 60 years. Diabetic subjects with any type of drug or alcohol dependence, on treatment with uric acid lowering drugs or diuretics or any other interfering pathology were excluded from the study. Pregnant and lactating females were also exempted from the study. Patients fulfilling the inclusion criteria and willing to participate were then subjected to thorough physical examination. Fasting blood samples were collected for estimation of blood glucose, uric acid, and HbA1c. For estimation of microalbumin levels, 24 hours urine samples were also collected. The patients were grouped based on the glycemic control. Patients with HbA1c ≤ 8.0% were considered as good control, while those with HbA1c > 8.0% were grouped as poor control.

The data obtained for various parameters in the two groups were presented as mean ± standard deviation and Student's t-test was applied. Pearson's correlation was applied to evaluate the association of HbA1c with serum uric acid and urine microalbumin levels. A p-value ≤ 0.05 was considered as statistically significant.

RESULTS

The primary aim of the research was to study the impact of glycemic control on microalbuminuria and serum uric acid levels in patients of type II DM (Graphs 1 and 2). Patients enrolled for the study were grouped based on the HbA1c levels as:

Group I (Good glycemic control) HbA1c ≤ 8.0 n = 48
Group II (Poor glycemic control) HbA1c > 8.0 n = 52

In the above-mentioned groups, mean age of patients was comparable and did not show any correlation with HbA1c or microalbuminuria. The HbA1c levels in the two groups were 6.40 ± 0.86 and 10.59 ± 1.40% respectively (p = 0.000) (Table 1). The mean fasting sugar levels also showed an obvious significant variation as reflected by the HbA1c levels (Table 1 and Graph 3).

In the poor glycemic control group (group II), 24-hour urine microalbumin was noted to be significantly higher (Table 1) and a positive correlation (r = 0.237) was observed between HbA1c and microalbuminuria (Table 2 and Graph 4). Similarly, the study also observed a significant correlation (r = 0.203) between HbA1c and serum uric acid (Table 2 and Graph 5) and, hence, suggested that a poor glycemic status in type II diabetics may lead to hyperuricemia, which in turn may serve as a cardiovascular and renal dysfunction risk factor.

Further, on applying Pearson's correlation, it was observed that microalbuminuria showed a significant correlation with serum uric acid (r = 0.338) (Table 2 and

**Graph 1:** Level of urinary microalbumin in type II DM patients in the groups based on glycemic control

Graph 2: Level of uric acid in type II DM patients in the groups based on glycemic control

Table 1: Distribution of different parameters in the groups based on glycemic control

Parameters	Group I (HbA1c ≤ 8.0%)	Group II (HbA1c > 8.0%)	p-value
No. of cases	40	60	
Age (years)	50.29 ± 9.41	49.17 ± 10.39	NS
Duration of disease (years)	6.79 ± 3.10	9.08 ± 3.00	0.000
Fasting blood sugar (mg/dL)	139.88 ± 36.73	245.75 ± 91.29	0.000
HbA1c (%)	6.40 ± 0.86	10.59 ± 1.40	0.000
Serum uric acid (mg/dL)	4.62 ± 1.21	5.35 ± 1.52	0.010
Uric microalbumin (mg/24 hours)	29.42 ± 26.57	63.37 ± 51.01	0.000

NS: Not significant

Graph 3: Fasting blood sugar levels in type II DM patients in the groups based on glycemic control

Table 2: Correlation coefficients for various factors

Factors	Correlation coefficient (r)	p-value
HbA1c *vs* uric acid	0.202	0.040
HbA1c *vs* microalbuminuria	0.237	0.017
Microalbuminuria *vs* uric acid	0.338	0.000
Microalbuminuria *vs* duration	0.042	NS

NS: Not significant

Graph 6). The mean duration of disease among the two groups based on glycemic control was significantly higher in the group with poor glycemic control (Table 1 and Graph 7). However, microalbuminuria did not show a significant correlation with the duration of disease (Table 2). This suggests that even in patients with shorter duration of disease, poor glycemic control may be responsible for the development of microalbuminuria and hence nephropathy. Hence, the findings of the study strongly emphasize the fact that complications of type II DM can be averted by proper management of the disease and by maintaining a strict glycemic control.

DISCUSSION

Type II diabetes is an independent risk factor for microvascular and macrovascular disease.[18,19] Microalbuminuria represents the simplest and most sensitive prognostic factor to evaluate the risk of overt nephropathy in diabetes, representing the first stage of progressive diabetic renal disease.[20]

Recent studies suggest that factors causing inflammation and endothelial dysfunction play a major role in development of DN.[11-13] Several studies have observed a strong association between hyperuricemia and progression of chronic renal failure.[21-24] Further elevated/

Graph 4: X–Y scatterplot for HbA1c *vs* microalbuminuria (r = 0.237, p = 0.017)

Graph 5: X–Y scatterplot for HbA1c *vs* serum uric acid (r = 0.203, p = 0.040)

Graph 6: X–Y scatterplot for microalbuminuria *vs* serum uric acid (r = 0.338, p = 0.000)

Graph 7: Duration of diabetes in type II DM patients in the groups based on glycemic control

raised serum uric acid in the early course of diabetes is said to be associated with later development of persistent microalbuminuria.[21,22]

In the present study, it was observed that diabetics with poor glycemic control (group II) had high microalbuminuria level compared with those with good glycemic control (group I). The above finding was in accordance with the finding of Kundu et al.[25] In a recent study by Naveen et al,[26] urinary microalbuminuria levels were reported to be 121.0 ± 49.89 mg/24 hours in poor glycemic control group compared with 47.14 ± 39.15 mg/24 hours in the good glycemic control group. The results of the present study were quite close to the above-mentioned findings.

Diabetic nephropathy is said to be a common consequence of long-standing DM. Elevated glucose levels in blood lead to binding of glucose to protein and resulting in excessive protein glycosylation, which in turn leads to elevated glycated end products. Increased deposition of these glycated end products on the glomerulus results in renal and glomerular hypertrophy and thickening of glomerular basement membrane. This results in leakage of low molecular weight protein, especially albumin.[26]

Further, in the present study, a linear correlation was observed between glycemic index (HbA1c levels) and microalbuminuria (r = 0.237). This above finding was similar to the finding of Naveen et al,[26] Kundu et al,[25] and Neupane et al.[27]

On comparing the mean levels of serum uric acid in the groups based on glycemic control, a significant variation was observed. The mean level of serum uric acid in group I was 4.62 ± 1.21 mg/dL compared with 5.35 ± 1.52 mg/dL in group II patients. Safi et al[28] reported serum uric acid levels of 6.2 ± 1.3 mg/dL in diabetic type II patients. Several studies have shown a positive association of serum uric acid with type II DM.[14,29]

The actual mechanism of hyperuricemia in diabetic patients is not clear. Yoo et al[30] studied the relationship between serum uric acid concentrations and insulin resistance in metabolic syndrome. The above association has also been explained based on the genetic predisposition.[31,32]

A significant correlation between microalbuminuria and serum uric acid was also observed. A common underlying pathogenesis of insulin resistance may be responsible for both elevation of serum uric acid and urine albumin excretion. On the contrary, hyperinsulinemia may result in decreased renal output and also increased synthesis of uric acid. The pathophysiological cause of renal dysfunction following hyperuricemia probably includes inhibition of endothelial nitric oxide, activation of renin–angiotensin system, and direct stimulation of endothelial cell and smooth muscle cells.[33] Both microalbuminuria and hyperuricemia have been independently associated with increased risk of progressive kidney diseases, which in turn may be responsible for ESRDs and cardiovascular morbidity and mortality. Similar to the present study, a positive correlation of serum uric acid and microalbuminuria in type II DM was shown in a study conducted by Fukui et al.[34]

From the findings of the present study, we therefore conclude that good glycemic control can be helpful in preventing microalbuminuria and hyperuricemia, hence diabetic nephropathy in chronic diabetes. The study proposes regular screening for microalbuminuria along with HbA1c estimation as important tools for management of DM.

CONCLUSION

The present study reported that a poor glycemic control in type II diabetics may lead to development

of microalbuminuria and hyperuricemia, which in turn may bring about changes resulting in progressive renal disease and other cardiovascular complications. The situation can be averted by maintaining a good glycemic control and adopting a healthy lifestyle. The study suggests a regular screening of HbA1c, microalbuminuria, and serum uric acid in type II diabetic patients for identification and timely management of patients at risk.

The study further proposes assessment of the association of microalbuminuria and hyperuricemia with other cardiovascular risk factors, such as components of lipid profile and blood pressure, etc. Urinary microalbumin levels for the present study were estimated on 24-hour urine samples. A new and more convenient replacement has now been introduced, i.e., albumin creatinine ratio (ACR), which can be estimated with spot urine sample. The study, therefore, suggests further research on correlation of HbA1c and serum uric acid with ACR. The effect of uric acid-lowering drugs and HbA1c variability on risk factors of DM and other cardiovascular complications may also be interesting to explore further.

REFERENCES

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004 Jan;27(Suppl 1):S5-S10.
2. Ramachandran A, Snehalatha C. Current scenario of diabetes in India. J Diabetes 2009 Mar;1(1):18-28.
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(Suppl 1):62-69.
4. Kaveeshwar SA, Cornwall J. The current status of diabetes mellitus in India. Australas Med J 2014;7(1):45-48.
5. Jalal DI, Rivard CJ, Johnson RJ, Maahs DM, McFann K, Rewers M, Snell-Bergeon JK. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant 2010 Jun;25(6):1865-1869.
6. Rahimi Z. ACE insertion/deletion (I/D) polymorphism and diabetic nephropathy. J Nephropathol 2012 Oct;1(3):143-151.
7. Rouhi H, Ganji F. Effect of N-acetyl cysteine on serum lipoprotein (a) and proteinuria in type 2 diabetic patients. J Nephropathol 2013 Jan;2(1):61-66.
8. Bouhanick, B, Berrut, G, Chameau, AM, Hallar, M, Bled, F, Chevet, B, Vergely, J, Rohmer, V, Fressinaud, P, Marre, M. Predictive value of testing random urine sample to detect microalbuminuria in diabetic patients on outpatient basis. Diabetes Metab 1992;18:54-58.
9. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG; DEMAND Investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006 Jun;69(11):2057-2063.
10. Charpentier G, Genès N, Vaur L, Amar J, Clerson P, Cambou JP, Guéret P; ESPOIR Diabetes Study Investigators. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes mellitus; a national wide French survey. Diabetes Metab 2003 Apr;29(2 Pt 1):152-158.
11. Kari J. Epidemiology of chronic kidney disease in children. J Nephropathol 2012 Oct;1(3):162-163.
12. Lim AK, Tesch GH. Inflammation in diabetic nephropathy. Mediators Inflamm 2012;2012:146154.
13. Nasri H. Hypertension and renal failure with right arm pulse weakness in a 65 years old man. J Nephropathol 2012 Oct;1(3):130-133.
14. Wei F, Chang B, Yang X, Wang Y, Chen L, Li WD. Serum uric acid levels were dynamically coupled with hemoglobin A1c in the development of type 2 diabetes. Sci Rep 2016 Jun 22;6:28549.
15. Gupta DK, Verma LK, Khosla PK, Dash SC. The prevalence of microalbuminuria in diabetes: a study from North India. Diabetes Res Clin Pract 1991;12:125-128.
16. John L, Rao PS, Kanagasabapathy AS. Prevalence of diabetic nephropathy in non insulin dependent diabetes. Indian J Med Res 1991 Feb;94:24-29.
17. Schmitz A, Vacth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabet Med 1988 Mar;5(2):126-134.
18. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke and death: a population based study of 13,000 men and women with 20 years follow up. Arch Intern Med 2004 Jul 12;164(13):1422-1426.
19. Stamler J. Impact of diabetes on cardiovascular mortality in MRFIT. Diabetes Care 2006;26:498-503.
20. Tobe SW, McFarlane PA, Naimark DM. Microalbuminuria in diabetes mellitus. CMAJ 2002 Sep 3;167(5).
21. Hovind P, Rossing P, Johnson RJ, Parving HH. Serum uric acid as a new player in the development of diabetic nephropathy. J Ren Nutr 2011 Jan;21(1):124-127.
22. Kuo CF, Luo SF, See LC, Ko YS, Chen YM, Hwang JS, Chou IJ, Chang HC, Chen HW, Yu KH. Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol 2011 Mar;40(2):116-121.
23. Bruno RM, Penno G, Daniele G, Pucci L, Lucchesi D, Stea F, Landini L, Cartoni G, Taddei S, Ghiadoni L, et al. Type 2 diabetes mellitus worsens arterial stiffness in hypertensive patients through endothelial dysfunction. Diabetologia 2012 Jun;55(6):1847-1855.
24. Khajehdehi P. Turmeric: reemerging of a neglected Asian traditional remedy. J Nephropathol 2012 Apr;1(1):17-22.
25. Kundu D, Roy A, Mandal T, Bandyopadhyay U, Ghosh E, Ray D. Relation of microalbuminuria to glycosylated hemoglobin and duration of type 2 diabetes. Niger J Clin Pract 2013 Apr-Jun;16(2):216-220.
26. Naveen P, Kannan N, Annam V, Bhanu Prakash G, Aravind Kumar R. Evaluation of glycated hemoglobin and microalbuminuria as early risk markers of nephropathy in type 2 diabetes mellitus. Int J Biol Med Res 2012;3(2):1724-1726.
27. Neupane S, Dubey RK, Gautam N, Agarwal KK, Jayan A, Shrestha S, Jha AC. Association between serum uric acid, urinary albumin excretion and glycated hemoglobin in type 2 diabetic patient. Niger Med J 2016 Mar-Apr;57(2):119-123.
28. Safi AJ, Mahmood R, Khan MA, Haq A. Association of serum uric acid with type II diabetes mellitus. J Postgrad Med Inst 2004;18:59-63.
29. Pavithra V, Revathy K, Swaminathan S. Association between uric acid and HbA1c in type 2 diabetes mellitus in comparison with controls. Int J Curr Microbiol Appl Sci 2016;5(4):585-589.
30. Yoo TW, Sung KC, Shin S. Relationship between Serum uric acid concentration and Insulin resistance and metabolic syndrome. Circ J 2005 Aug;69(8):928-933.

31. Bo S, Cavello PP, Gentile L, Repetti E, Pagano G. Hypouri-cemia and hyperuricemia in type 2 diabetes: two different phenotypes. Eur J Clin Invest 2001 Apr;31(4):318-321.

32. Edwards CR, Baird JD, Frier BM, Shepherd J, Toft AD. Endocrine and metabolic diseases including diabetes mellitus. In: Davidson's principles and practice of medi-cine. 19th ed. Edinburgh (UK): Churchill Livingstone; 2002. p. 644-648.

33. Bonakdaran S, Hami M, Shakeri MT. Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus. Iran J Kidney Dis 2011 Jan;5(1):21-24.

34. Fukui M, Tanaka M, Shiraishi E, Harusato I, Hosoda H, Asano M, Kadono M, Hasegawa G, Yoshikawa T, Nakamura N. Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. Metabolism 2008 May;57(5):625-629.